← All trials
NCT05225389
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2022
- Primary completion
- Jan 18, 2022
- Completion date
- Jan 24, 2022
- First posted
- Feb 4, 2022
- Last posted
- Feb 4, 2022
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cognition TherapeuticsLead sponsor
- Cognition TherapeuticsStudy director
- National Institute on Aging (NIA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.